Connect with us


Why the Dimerix (ASX:DXB) share price is rocketing higher



The Dimerix Ltd (ASX: DXB) share price has shot 6% higher to start the day after an update from the drug discovery company.

Why is the Dimerix share price surging higher?

Dimerix provided an update on its Phase 3 ACE2 renin angiotensin system (RAS) modulation study domain in Europe. The first 24 patients have been recruited into the study in patients with COVID-19 pneumonia, which incorporates DMX-200. DMX-200 is Dimerix’s chemokine receptor (CCR2) blocker that has been included in the global COVID-19 trial. 

The Dimerix share price has rocketed higher on the news with 22 patients from the Netherlands and 2 in the UK. Patients receive one of three randomly assigned interventions or a control as part of the study.

It comes as…

Click here to view the original article.

Continue Reading

You might also like ...

Article feature image
Woman claims she destroyed $33m winning lotto ticket in laundry – Yahoo News Australia
Article feature image
2 high-quality ASX 200 shares to buy – The Motley Fool Australia